Insulin resistance starts where fat outgrows its blood supply
In short
When adipose tissue expands faster than new vessels can grow into it, the tissue turns hypoxic, and that hypoxia is the starting point for chronic inflammation and adipocyte dysfunction. In this study, mice with the IL-19 gene deleted were lean and eating standard chow yet showed reduced adipose vascularization, hypoxia, fibrosis, inflammation, adipocyte hypertrophy — plus glucose intolerance and insulin resistance. Treating obese wild-type mice with IL-19 improved vascularization and attenuated both inflammation and glucose intolerance. The trigger was not total fat mass but fat tissue that outgrew its blood supply.
The sequence runs like this: visceral fat expands, vessel growth fails to keep pace, the tissue goes hypoxic, and hypoxia switches on inflammation. That inflammation appears to be a call for new vessels, but in obesity the vessels never arrive in sufficient number, leaving chronic low-grade inflammation and dysfunctional fat cells behind. Metabolic and cardiovascular complications, insulin resistance among them, sit at the end of that chain. The problem is not that fat exists — it is that fat grew faster than its supply line.
Why did lean mice become insulin resistant?
This is the study's central observation. The team deleted IL-19, an interleukin they showed is expressed in white adipose tissue. Lean knockout mice on a standard diet then developed markedly reduced adipose vascularization along with hypoxia, fibrosis, inflammation and adipocyte hypertrophy — and went on to glucose intolerance and insulin resistance. Metabolism broke down without any weight gain. From the other direction, wild-type mice made obese on a high-fat diet showed the same pattern: less vascularization, inflammation, glucose intolerance, insulin resistance. Two different routes, one destination.
Could it be reversed?
- Recombinant IL-19 — in obese wild-type mice it improved vascularization, attenuated adipose tissue inflammation, and reduced glucose intolerance.
- Cultured adipocytes — IL-19 increased glucose uptake, human adipocytes included.
- Mechanism — the effect tracked with upregulated expression and function of IRS2 and GLUT-4, the textbook insulin-signalling and glucose-transport route.
The framing the authors chose is uncoupling inflammation from angiogenesis. Attempts to switch off adipose inflammation have tended to switch off the vessel-building signal with it; an anti-inflammatory interleukin, they argue, allows the combination that matters — more vessels, less inflammation. All of this remains mice and cultured cells. Nobody has given IL-19 to a person here.
What does that mean for a lifter?
Look at the structure rather than the drug. If the real problem is fat tissue expanding past its blood supply, there are only two directions: slow the expansion, or grow the supply. Managing how fast fat accumulates in a bulk is the first (the ratio when adding); raising capillary density and vascular function through training is the second (resistance training and artery health, zone 2 for lifters). A scale shows none of this — at identical body weight, whether fat cells have passed what their scaffold can hold is a separate question, and joint pain rides on inflammation before it rides on load.
This is a mouse and cell-culture study. IL-19 is not a treatment given to people, and what was established here is a mechanistic hypothesis, not a therapy.
Frequently asked questions
Why does gaining fat cause insulin resistance?
Because vessel growth cannot keep pace with expanding fat tissue, the tissue becomes hypoxic, and that hypoxia drives chronic inflammation and adipocyte dysfunction. This study places the start of that chain at an inadequate blood supply.
Can a lean person become insulin resistant?
In this study, mice lacking IL-19 stayed lean on standard chow yet developed reduced adipose vascularization, hypoxia and inflammation along with glucose intolerance and insulin resistance. That points at tissue state rather than body weight, though it has not been confirmed in humans.
What is IL-19?
It is an anti-inflammatory interleukin, shown here to be expressed in white adipose tissue as well. The authors present it as a protective adipokine that maintains vascularization while holding inflammation down.
Does exercise affect this pathway?
The study did not test exercise. But since the axis in question is blood supply, training that raises capillary density and vascular function sits on the same axis. This paper does not demonstrate that effect.
Is IL-19 available as a treatment?
Not yet. The findings are at the level of mice and cultured cells, with no clinical evidence in people.
Source: PubMed